Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to a specific combination vaccine regimen evaluated by Merck Sharp & Dohme LLC in a Phase I observational study (NCT01832831). The regimen consists of three distinct vaccine products: Twinrix (a combined Hepatitis A and Hepatitis B vaccine), a Tetanus and Diphtheria (Td) booster, and Dukoral (an oral cholera vaccine). The study aimed to develop biomarker-based prediction rules for vaccine hyporesponse in healthy elderly individuals by measuring antibody titers across these diverse antigenic challenges. Twinrix provides active immunization against Hepatitis A and B; Td provides a booster against Clostridium tetani and Corynebacterium diphtheriae; and Dukoral provides protection against Vibrio cholerae and heat-labile enterotoxin-producing E. coli.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Twinrix-Merck Sharp & Dohme LLC-tetanus-diphtheria-hepatitis A-hepatitis B-cholera.